Welcome to our dedicated page for Lixte Biotechnology Hldgs SEC filings (Ticker: LIXTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles the U.S. SEC filings for LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT, LIXTW), a clinical-stage biopharmaceutical company focused on cancer therapies. Through documents such as Forms S-1, S-3 and 8-K, LIXTE provides detailed information on its oncology programs, capital structure, financings and governance.
In its registration statements on Form S-1 and Form S-3, LIXTE outlines its company overview and risk factors, describing a product pipeline centered on protein phosphatase 2A (PP2A) inhibitors and the lead candidate LB-100. These filings explain how LB-100 is being developed to enhance chemotherapy, radiation and immune checkpoint blockade, summarize proof-of-concept clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma, and discuss the company’s reliance on equity financing and stock-based compensation.
Current reports on Form 8-K document material events such as private placements and registered direct offerings of common stock, preferred stock and warrants, entry into Securities Purchase Agreements and Placement Agent Agreements, and related gross proceeds. Other 8-K filings address Board and management changes, the establishment of a Scientific Advisory Committee, publication of scientific findings in Nature that support the LB-100 mechanism, and the company’s initial purchase of digital currencies as part of its updated treasury policy.
These filings also provide insight into LIXTE’s status as a smaller reporting company, its compliance with Nasdaq Capital Market listing rules, and the terms of its outstanding securities, including pre-funded warrants, common stock warrants and preferred stock conversion rights. On Stock Titan, users can access these filings as they are posted to EDGAR and use AI-powered summaries to quickly understand complex sections of registration statements, 8-K disclosures and related exhibits, as well as to review insider-related information where reported on standard SEC forms.
Lixte Biotechnology Holdings, Inc. filed a current report describing a recent treasury move into digital assets. On September 10, 2025, the company issued a press release announcing an initial purchase of digital currency totaling $2.6 million.
The disclosure is furnished under Regulation FD, meaning it is provided for informational purposes and is not treated as filed financial information under securities laws. The report also includes standard forward-looking statement cautions about risks and uncertainties that could cause actual results to differ from expectations.
Peter Stazzone, appointed Chief Financial Officer of Lixte Biotechnology Holdings, Inc., was granted options to buy 50,000 shares of common stock at an exercise price of $4.45 per share. The options vest in four equal tranches: 25% on 09/01/2025, 25% on 12/15/2025, 25% on 03/15/2026, and 25% on 06/15/2026, subject to continuous service and possible acceleration on certain events. Each option covers one share and the options expire five years after the grant date, making the exercisable common shares underlying the grant 50,000.
Peter Stazzone filed a Form 3 reporting an initial statement of beneficial ownership for Lixte Biotechnology Holdings, Inc. (symbol shown as LIXT) related to an event on 09/01/2025. The filing identifies Mr. Stazzone as an officer with the title Chief Financial Officer and indicates the form was filed by one reporting person. The Form 3 states no securities are beneficially owned by the reporting person. The filing is signed and dated 09/04/2025.
Lixte Biotechnology Holdings, Inc. (LIXTW) Form 3 shows that Felix Lourdes, identified as a Director, filed an initial statement dated 09/01/2025 but reported no securities beneficially owned in the issuer. The signature block is dated 09/04/2025. The filing confirms the director relationship but discloses zero direct or indirect holdings in the company.
Jason David Sawyer, a newly appointed director of Lixte Biotechnology Holdings, Inc. (ticker: LIXT/LIXTW), was granted options to purchase 25,000 shares on 08/15/2025. The options have an exercise price of $3.59 per share, become exercisable immediately for 50% of the grant and vest the remaining 50% in increments—12.5% on 12/31/2025 and 12.5% on the last day of each subsequent calendar quarter—subject to continuous service, and expire on 08/15/2030. The grant was made in connection with Sawyer's appointment to the company’s board. The Form 4 was signed by the reporting person on 08/18/2025.
Michael Andrew Holloway was appointed to the board of Lixte Biotechnology Holdings, Inc. and on August 15, 2025 was granted options to purchase 25,000 shares of common stock at an exercise price of $3.59 per share. The options vest 50% immediately on the effective date and the remaining 50% vests in increments of 12.5% on December 31, 2025 and on the last day of each subsequent calendar quarter until fully vested. The options are exercisable beginning August 15, 2025 and expire on August 15, 2030. The Form 4 was signed by Mr. Holloway on August 18, 2025.
FAQ
What is the current stock price of Lixte Biotechnology Hldgs (LIXTW)?
